theory clinical_46_5
imports Main

begin

typedecl entity
typedecl event

consts
  PARPInhibitors :: "entity ⇒ bool"
  DSBs :: "entity ⇒ bool"
  SSBreakRepair :: "entity ⇒ bool"
  DNA :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Prevent :: "event ⇒ bool"
  Rely :: "event ⇒ bool"
  On :: "event ⇒ entity ⇒ bool"
  HRR :: "entity ⇒ bool"
  NHEJ :: "entity ⇒ bool"
  Repair :: "event ⇒ bool"
  SyntheticLethality :: "entity ⇒ bool"
  GeneticEvents :: "entity ⇒ bool"
  LossOfPALB2 :: "entity ⇒ bool"
  CellDeath :: "entity ⇒ bool"
  Occurs :: "event ⇒ bool"
  CoOccurrence :: "event ⇒ bool"
  Results :: "event ⇒ bool"
  Reliance :: "event ⇒ bool"
  Mechanism :: "entity ⇒ bool"
  Cells :: "entity ⇒ bool"
  PARP1Inhibition :: "entity ⇒ bool"
  Lead :: "event ⇒ bool"
  Combined :: "event ⇒ bool"
  Force :: "event ⇒ bool"
  Depend :: "event ⇒ bool"
  Leading :: "event ⇒ bool"
  Patients :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"

(* Explanation 1: PARP inhibitors cause replication‐associated DSBs by preventing SS break repair, relying on defective HRR and error-prone NHEJ to repair DNA. *)
axiomatization where
  explanation_1: "∃x y z w e1 e2 e3 e4 v1 v2. PARPInhibitors x ∧ DSBs y ∧ SSBreakRepair z ∧ DNA w ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Rely e3 ∧ Agent e3 x ∧ On e3 v1 ∧ HRR v1 ∧ On e3 v2 ∧ NHEJ v2 ∧ Repair e4 ∧ Agent e4 x ∧ Patient e4 w"

(* Explanation 2: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of PALB2, results in cell death due to the reliance on a singular mechanism to repair cumulative DNA damage. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3 e4 e5 v. SyntheticLethality x ∧ GeneticEvents y ∧ LossOfPALB2 z ∧ CellDeath w ∧ Occurs e1 ∧ Agent e1 x ∧ CoOccurrence e2 ∧ Agent e2 y ∧ Results e3 ∧ Agent e3 y ∧ Patient e3 w ∧ Reliance e4 ∧ Agent e4 y ∧ Mechanism v ∧ On e4 v ∧ Repair e5 ∧ Agent e5 y ∧ Patient e5 v1 ∧ DNA v1"

(* Explanation 3: The loss of PALB2 in cells can lead to synthetic lethality when combined with PARP1 inhibition, as it forces cells to depend on a singular, often inadequate, DNA repair mechanism, leading to cell death. *)
axiomatization where
  explanation_3: "∃x y z w v u e1 e2 e3 e4 e5 e6 v1. LossOfPALB2 x ∧ Cells y ∧ SyntheticLethality z ∧ PARP1Inhibition w ∧ CellDeath v ∧ Lead e1 ∧ Agent e1 x ∧ Patient e1 z ∧ Combined e2 ∧ Agent e2 x ∧ Patient e2 w ∧ Force e3 ∧ Agent e3 x ∧ Patient e3 y ∧ Depend e4 ∧ Agent e4 y ∧ Mechanism u ∧ On e4 u ∧ Repair e5 ∧ Agent e5 y ∧ Patient e5 v1 ∧ DNA v1 ∧ Leading e6 ∧ Agent e6 y ∧ Patient e6 v"

theorem hypothesis:
  assumes asm: "Patients x ∧ LossOfPALB2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z"
  (* Hypothesis: Patients with loss of PALB2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)
  shows "∃x y z e1 e2 e3 e4 w v1. Patients x ∧ LossOfPALB2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Benefit e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Cause e2 ∧ Agent e2 z ∧ Patient e2 x ∧ Rely e3 ∧ Agent e3 x ∧ Mechanism w ∧ On e3 w ∧ Repair e4 ∧ Agent e4 x ∧ Patient e4 v1 ∧ DNA v1"
proof -
  (* From the premise, we have known information about patients, loss of PALB2, PARP1 inhibition, and synthetic lethality. *)
  from asm have "Patients x ∧ LossOfPALB2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z" by force
  (* Explanation 3 provides a logical relation: Implies(And(I, J), And(D, K, G)), which means the loss of PALB2 in cells and PARP1 inhibition leads to synthetic lethality, forcing cells to depend on a singular, often inadequate, DNA repair mechanism, and cell death. *)
  (* Since we have LossOfPALB2 x and PARP1Inhibition y, we can infer the consequences of synthetic lethality and reliance on a singular mechanism. *)
  then have "SyntheticLethality z ∧ Depend e3 ∧ Agent e3 x ∧ Mechanism w ∧ On e3 w ∧ Repair e4 ∧ Agent e4 x ∧ Patient e4 v1 ∧ DNA v1" sledgehammer
  (* The hypothesis requires showing that patients with loss of PALB2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)
  (* We have already established the reliance on a singular mechanism and synthetic lethality. *)
  (* Therefore, we can conclude that patients may benefit from this mechanism. *)
  then have "Benefit e1 ∧ Agent e1 x ∧ Patient e1 y" <ATP>
  then show ?thesis <ATP>
qed

end
